Paola Brandi
Madrid, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Microbiota translocation following intestinal barrier disruption promotes Mincle-mediated training of myeloid progenitors in the bone marrow.
Journal: Immunity
Published: August 02, 2024
The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity.
Journal: Frontiers in immunology
Published: July 27, 2021
DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells.
Journal: Journal for immunotherapy of cancer
Published: March 23, 2021
Bacterial Mucosal Immunotherapy with MV130 Prevents Recurrent Wheezing in Children: A Randomized, Double-Blind, Placebo-controlled Clinical Trial.
Journal: American journal of respiratory and critical care medicine
Published: March 11, 2021
Trained immunity induction by the inactivated mucosal vaccine MV130 protects against experimental viral respiratory infections.
Journal: Cell reports
Published: December 26, 2020
Perspectives in Peptide-Based Vaccination Strategies for Syndrome Coronavirus 2 Pandemic.
Journal: Frontiers in pharmacology
Published: June 30, 2020
Targeting SHIP-1 in Myeloid Cells Enhances Trained Immunity and Boosts Response to Infection.
Journal: Cell reports
Published: April 10, 2018
Human dendritic cells activated with MV130 induce Th1, Th17 and IL-10 responses via RIPK2 and MyD88 signalling pathways.
Journal: European journal of immunology
Published: March 01, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026